VivoSeq
Rare Disease

Schnitzler Syndrome

4

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Schnitzler syndrome is an early-stage landscape with 4 programs across 2 companies. The most active players are Novartis, Roche.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

75/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

2 programs

Phase 2Roche logo

Roche

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 24

Canakinumab

Novartis

Tocilizumab

Roche

Ilaris

Novartis

RPH-104

Unknown Sponsor

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

5

clinical trials

Completed3 · 60%
Withdrawn1 · 20%
Recruiting1 · 20%

Clinical Trials

Trial Activity

Efficacy and Safety of Canakinumab in Schnitzler Syndrome
Completed·RRadboud University Medical Center·Phase 2·NCT01276522·8 enrolled
Ilaris® Effects in Schnitzler Syndrome (ILESCH)
Completed·—·Phase 2·NCT01390350·20 enrolled
Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
Withdrawn·RR-Pharm Overseas, Inc.·Phase 2·NCT04213274
Ilaris (Canakinumab) in the Schnitzler Syndrome
Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT01245127·1 enrolled
Specified Use-Results Study of ILARIS Solution for S.C. Injection (Schnitzler's Syndrome)
Recruiting·Novartis logoNovartis·N/A·NCT07598422·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)